Home
Categories
EXPLORE
True Crime
Comedy
Business
Society & Culture
Sports
Health & Fitness
Technology
About Us
Contact Us
Copyright
© 2024 PodJoint
Loading...
0:00 / 0:00
Podjoint Logo
US
Sign in

or

Don't have an account?
Sign up
Forgot password
https://is1-ssl.mzstatic.com/image/thumb/Podcasts211/v4/64/33/ba/6433ba0f-405d-81e6-bc82-4d4f04775f0a/mza_2622887070788468434.jpg/600x600bb.jpg
In the Interim...
Berry
31 episodes
4 days ago
A podcast on statistical science and clinical trials. Explore the intricacies of Bayesian statistics and adaptive clinical trials. Uncover methods that push beyond conventional paradigms, ushering in data-driven insights that enhance trial outcomes while ensuring safety and efficacy. Join us as we dive into complex medical challenges and regulatory landscapes, offering innovative solutions tailored for pharma pioneers. Featuring expertise from industry leaders, each episode is crafted to provide clarity, foster debate, and challenge mainstream perspectives, ensuring you remain at the forefront of clinical trial excellence.
Show more...
Mathematics
Health & Fitness,
Medicine,
Science
RSS
All content for In the Interim... is the property of Berry and is served directly from their servers with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
A podcast on statistical science and clinical trials. Explore the intricacies of Bayesian statistics and adaptive clinical trials. Uncover methods that push beyond conventional paradigms, ushering in data-driven insights that enhance trial outcomes while ensuring safety and efficacy. Join us as we dive into complex medical challenges and regulatory landscapes, offering innovative solutions tailored for pharma pioneers. Featuring expertise from industry leaders, each episode is crafted to provide clarity, foster debate, and challenge mainstream perspectives, ensuring you remain at the forefront of clinical trial excellence.
Show more...
Mathematics
Health & Fitness,
Medicine,
Science
https://is1-ssl.mzstatic.com/image/thumb/Podcasts211/v4/64/33/ba/6433ba0f-405d-81e6-bc82-4d4f04775f0a/mza_2622887070788468434.jpg/600x600bb.jpg
The Not So Promising Zone Design
In the Interim...
39 minutes
4 days ago
The Not So Promising Zone Design

In this episode of "In the Interim…", Dr. Scott Berry examines the mathematical foundations and efficiency claims of the promising zone design for adaptive sample size in clinical trials. Scott unpacks the conditional power thresholds that trigger sample size increases without the need to adjust alpha, as originally presented by Mehta & Pocock. He systematically demonstrates, via simulation, that the promising zone rarely provides meaningful efficiency gains over fixed designs and is consistently outperformed by group sequential designs that allocate alpha across multiple analyses. Using a driving-route analogy, Scott highlights the practical flaw in making pivotal trial decisions earlier than necessary due to arbitrary statistical rules rather than observing current data. He underlines that at Berry; simulation efforts have yet to reveal a scenario where the promising zone design is more efficient than a thoughtfully constructed group sequential or Goldilocks trial. The episode urges trialists to simulate, compare, and optimize—not to accept appealing mathematical tricks without rigorous evaluation.

Key Highlights

  • Explanation of the promising zone’s conditional power mechanism and alpha control.
  • Simulation-based comparison of power and average sample size across design types.
  • Direct comparison of group sequential vs. promising zone designs.
  • Discussion of futility rules and their impact on design choice.
  • Commentary on Goldilocks designs for incomplete data.

For more, visit: https://www.berryconsultants.com/

In the Interim...
A podcast on statistical science and clinical trials. Explore the intricacies of Bayesian statistics and adaptive clinical trials. Uncover methods that push beyond conventional paradigms, ushering in data-driven insights that enhance trial outcomes while ensuring safety and efficacy. Join us as we dive into complex medical challenges and regulatory landscapes, offering innovative solutions tailored for pharma pioneers. Featuring expertise from industry leaders, each episode is crafted to provide clarity, foster debate, and challenge mainstream perspectives, ensuring you remain at the forefront of clinical trial excellence.